Login to Your Account



No forward 'Momenta' for necuparanib as phase II enrollment halted

By Marie Powers
News Editor

Thursday, August 4, 2016

Momenta Pharmaceuticals Inc. heeded the recommendation of an independent DSMB and stopped enrollment in the phase II trial of necuparanib in patients with advanced metastatic pancreatic cancer.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription